It sounds almost too simple: a device that flickers light and plays sound at 40 cycles per second. But the results from clinical trials are extraordinary — and one of the world's biggest Alzheimer's trials is now racing toward a definitive answer.
Cognito Therapeutics, an MIT spin-off, this week announced a **$105 million Series C funding round** to prepare for the FDA submission of its *Spectris* device — the culmination of decades of research into what scientists call Gamma Entrainment Using Sensory Stimuli, or GENUS.
The premise is remarkable: by exposing the brain to precisely tuned 40Hz flickering light and sound — the frequency of gamma brainwaves — researchers have been able to slow or even reverse some of the hallmarks of Alzheimer's disease.
**The Numbers That Stopped Scientists in Their Tracks**
In Cognito's Phase 2 OVERTURE trial, daily use of the Spectris device over six months produced results that stunned researchers:
- **76% reduction** in cognitive decline compared to control groups - **77% reduction** in functional decline - **69% reduction** in whole-brain atrophy
Those numbers — achieved without drugs, injections, or surgery — earned the device **FDA Breakthrough Device Designation**, a status reserved for technologies that may offer substantial improvement over existing options for serious conditions.
'This isn't about managing symptoms. The structural preservation we're seeing in the brain suggests something much more fundamental is happening.' — Cognito Therapeutics, published in *Frontiers in Neurology*
**The Science: Why 40Hz?**
The science behind GENUS traces back to the lab of MIT neuroscientist Li-Huei Tsai. Her team discovered that 40Hz gamma oscillations — the brain's natural frequency for sensory processing and memory — become disrupted in Alzheimer's patients. When you restore those oscillations externally via flickering light and matched sound, remarkable things happen.
In animal studies, just one hour of daily 40Hz stimulation reduced amyloid-beta plaques (the sticky proteins strongly associated with Alzheimer's disease) by up to 50%. It also triggered a surge in microglial activity — the brain's immune cells, which physically clear cellular debris — and reduced neuroinflammation.
Clinical studies in humans have confirmed gamma entrainment is achievable with the device, and that the effects on biomarkers — including amyloid levels and tau proteins — are real and measurable.
**The HOPE Study: 670 Patients, the Final Answer**
Everything now rests on Cognito's pivotal Phase 3 trial: the HOPE Study. It enrolled **670 patients** across 70 US sites — the largest randomised trial of non-pharmacological Alzheimer's therapy ever conducted. Enrollment completed in July 2025, and topline data is expected in **late 2026**.
If the Phase 3 results echo the Phase 2 signal, the FDA path is clear. Cognito is already using the $105M raise to manufacture devices at scale and prepare for commercialisation in 2027.
**Why This Matters So Much**
Alzheimer's disease affects over **55 million people worldwide**. For decades, every drug trial has largely failed or offered only modest delays. A safe, affordable, drug-free device that patients can use at home for one hour a day — and that may protect the physical structure of the brain — would be transformative.
The Phase 3 data can't come fast enough. But the signal so far is the most hopeful non-pharmaceutical finding in Alzheimer's research in a generation. 🧠💙
Sources: HLTH.com · MIT News · Cognito Therapeutics · medtechdive.com · clinicaltrialsarena.com